nuBeam BNCT System – Accelerator-Based Boron Neutron Capture Therapy Platform

Overview

The nuBeam BNCT System is a fully integrated, accelerator-based Boron Neutron Capture Therapy (BNCT) platform engineered for clinical translation and research-grade neutron beam delivery. Unlike legacy reactor-based neutron sources, nuBeam utilizes a compact 2.6 MeV electrostatic proton accelerator coupled with a rotating solid lithium target to generate epithermal neutrons via the ⁷Li(p,n)⁷Be reaction. This physics-driven design enables on-site installation in hospital environments without nuclear reactor infrastructure, meeting stringent radiological safety and spatial footprint requirements. The system delivers a well-characterized, forward-peaked epithermal neutron beam optimized for deep-tissue penetration and thermal neutron flux amplification within boron-loaded tumor cells. Its modular architecture includes beam shaping assemblies (BSA), real-time neutron fluence monitoring, patient positioning robotics with sub-millimeter reproducibility, and comprehensive radiation shielding validated per IAEA SSG-46 and ICRP Publication 118 guidelines.

Key Features

• 2.6 MeV Electrostatic Proton Accelerator: High-stability DC accelerator delivering up to 30 mA proton current with long-term beam stability (<±0.5% over 60 min), enabling consistent neutron yield and treatment repeatability.
• Rotating Solid Lithium Target: Actively cooled, high-thermal-conductivity Li metal target rotating at >3000 rpm to dissipate localized beam power density; engineered for >10,000 hours of operational lifetime under continuous irradiation.
• Integrated Beam Shaping Assembly (BSA): Composed of Al/AlF₃/Pb/CD₂/Bi layers to moderate and filter the neutron spectrum—reducing fast neutron and gamma contamination while enhancing epithermal neutron fluence (>1 × 10⁹ n/cm²/s at collimator exit).
• Patient Positioning System: Six-degree-of-freedom robotic couch with laser-guided alignment, integrated CT/MRI co-registration interface, and real-time motion compensation capability compliant with IEC 62553:2019 for radiotherapy equipment.
• Shielding Solution: Pre-engineered, site-adaptable concrete-steel-borosilicate composite vault designed to meet local regulatory dose limits (<20 µSv/h outside controlled area) and certified by Finnish Radiation and Nuclear Safety Authority (STUK) and equivalent EU national authorities.
• Operational Efficiency: Designed for low total cost of ownership—no enriched uranium or fissile material handling, minimal radioactive waste generation, and simplified regulatory licensing pathway compared to reactor-based BNCT facilities.

Sample Compatibility & Compliance

The nuBeam system supports human-scale phantoms, preclinical rodent models (with optional collimator inserts), and ex vivo tissue samples for dosimetric validation and radiobiological assay development. All hardware components conform to essential requirements of the EU Medical Device Regulation (MDR 2017/745) Class III for active therapeutic devices. Beam calibration protocols follow AAPM TG-198 and IAEA TRS-398 standards. Shielding performance documentation satisfies EURATOM Directive 2013/59 and Finnish Decree 1102/2019 on ionizing radiation use. System software architecture is compatible with hospital PACS and DICOM-RT workflows.

Software & Data Management

nuBeam Control Suite provides full lifecycle management—from beam commissioning and QA/QC logging to treatment planning integration via DICOM-RT import/export. The platform features audit-trail functionality compliant with FDA 21 CFR Part 11 and EU Annex 11 for electronic records and signatures. Treatment logs include timestamped neutron fluence, beam current, target temperature, collimator position, and couch coordinates—all exportable in CSV or XML for independent dosimetry verification. Optional integration with Monte Carlo simulation tools (e.g., MCNP6, SERA) enables patient-specific dose calculation using boron concentration maps from PET imaging (e.g., ¹⁸F-BPA uptake data).

Applications

• Clinical BNCT trials for recurrent glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSCC), and melanoma metastases.
• Preclinical radiobiology studies investigating boron compound pharmacokinetics, microdistribution, and RBE determination in small-animal models.
• Neutron beam characterization and dosimeter intercomparison programs accredited under ISO/IEC 17025.
• Development and validation of real-time neutron detection systems (e.g., fission chambers, scintillation detectors) for in-beam monitoring.
• Training platform for medical physicists and radiation oncologists in neutron therapy physics and safety protocols.

FAQ

What regulatory approvals does the nuBeam system hold for clinical use?

The nuBeam platform has received CE marking under MDR 2017/745 as a Class III active therapeutic device and is approved for clinical trials in Finland, Sweden, and Japan. Full marketing authorization pathways are underway in the EU and UK.
Can nuBeam be installed in an existing hospital radiotherapy bunker?

Yes—its compact footprint (≤45 m² vault floor area) and absence of reactor infrastructure allow retrofitting into modified LINAC vaults, subject to structural and shielding reinforcement assessment.
Does the system support real-time neutron fluence monitoring during treatment?

Yes—integrated fission chamber arrays and activation foil readers provide continuous, traceable fluence measurement with ≤2% statistical uncertainty per 10-second interval.
What boron delivery agents are compatible with nuBeam’s beam characteristics?

The epithermal spectrum is optimized for ¹⁰B-labeled compounds including BPA-fructose complex and GB-10, with demonstrated efficacy in phase II trials using standard infusion protocols.
Is remote operation and service support available?

All control systems support secure TLS-encrypted remote diagnostics and preventive maintenance scheduling via encrypted cloud portal, with on-site engineering support provided by STUK-certified field service engineers across EEA member states.